Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares saw strong trading volume on Wednesday . Approximately 937,938 shares changed hands during trading, an increase of 296% from the previous session’s volume of 236,583 shares.The stock last traded at $22.4425 and had previously closed at $23.26.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CHGCY. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Chugai Pharmaceutical currently has a consensus rating of “Buy”.

Chugai Pharmaceutical Stock Performance

The business’s 50 day moving average is $24.12 and its 200-day moving average is $26.72. The firm has a market capitalization of $75.14 billion, a price-to-earnings ratio of 25.37 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. Equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.